GEISTWERT Rechtsanwälte Lawyers Avvocati

https-www.unifiedpatentcourt.org-en-node-182920-1b89a804188b

Amgen N.V., Amgen S.R.L, Amgen GmbH, Amgen B.V., Amgen S.A.S., Amgen Inc., Amgen Europe B.V. v. Regeneron Pharmaceuticals Inc. and Sanofi Biotechnology SAS

Date
2026-03-24
Division
Luxembourg (LU)
Type of action
Appeal RoP220.1
Language
EN

Metadata

Case IDhttps-www.unifiedpatentcourt.org-en-node-182920-1b89a804188b
Case number
Registry number
Order reference
Keywords
Headnotes

Documents and full text

Extractor: pypdf | Pages: 5

Decision of the Court of Appeal of the Unified Patent Court issued on 24 March 2026 Withdrawal pursuant to R. 265 RoP and Application for reimbursement of Court fees (R. 370 RoP) APPELLANTS (AND DEFENDANTS IN THE MAIN PROCEEDINGS BEFORE THE COURT OF FIRST INSTANCE) 1. Amgen N.V., Diegem, Belgium 2. Amgen S.R.L, Milan, Italy 3. Amgen GmbH, Munich, Germany 4. Amgen B.V., Breda, The Netherlands 5. Amgen S.A.S., Courbevoie, France 6. Amgen Inc., California, United States of America 7. Amgen Europe B.V., Breda, The Netherlands (hereinafter jointly referred to as “Amgen”) all represented by Johannes Heselberger, attorney at law, and other attorneys at law of the law firm Bardehle Pagenberg, Munich, Germany, and of Brinkhof, Amsterdam, The Netherlands RESPONDENTS (AND CLAIMANTS IN THE MAIN PROCEE ...